Impact of Free Thyroxine on the Outcomes of Left Atrial Ablation Procedures

Am J Cardiol. 2015 Dec 15;116(12):1863-8. doi: 10.1016/j.amjcard.2015.09.028. Epub 2015 Oct 9.

Abstract

The prevalence of atrial fibrillation (AF) is increased in hyperthyroidism. The degree to which thyroid hormones affect the outcomes of left atrial (LA) ablation is still unclear. From September 2010 to September 2013, 1,095 patients who underwent LA ablation (59.7% paroxysmal AF, 32.3% persistent AF, and 8.0% LA tachycardia) had their serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels measured in the 48 hours before the procedure. Patients were followed until they presented the first AF relapse after a blanking period of 3 months. TSH and FT4 were assessed as predictors of arrhythmia relapse and were adjusted for possible confounders. During a mean follow-up of 12.5 ± 7.9 months, 28.9% of patients presented an atrial arrhythmia relapse. TSH was not a predictor of relapse. In contrast, after adjustment, FT4 (median = 11.8 ng/L and interquartile range 10.6 to 14.6 ng/L) remained a predictor of relapse with 15% increase per quartile (hazard ratio 1.15, 95% confidence interval 1.03 to 1.29, p = 0.014). In conclusion, FT4 levels influence the success rate of LA ablation procedures, even when in the normal range.

MeSH terms

  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / etiology
  • Atrial Fibrillation / surgery*
  • Biomarkers / blood
  • Catheter Ablation / methods*
  • Catheter-Related Infections
  • Female
  • Follow-Up Studies
  • France / epidemiology
  • Heart Atria / physiopathology
  • Heart Atria / surgery*
  • Humans
  • Hyperthyroidism / blood
  • Hyperthyroidism / complications*
  • Male
  • Middle Aged
  • Prevalence
  • Retrospective Studies
  • Tachycardia, Paroxysmal / blood
  • Tachycardia, Paroxysmal / physiopathology
  • Tachycardia, Paroxysmal / surgery*
  • Thyroxine / blood*

Substances

  • Biomarkers
  • Thyroxine